- Home
- MULN vs QLGN Comparison
MULN vs QLGN Comparison
Compare MULN & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MULN
- QLGN
- Stock Information
- Founded
- MULN 2014
- QLGN 1996
- Country
- MULN United States
- QLGN United States
- Employees
- MULN N/A
- QLGN 4
- Industry
- MULN Auto Manufacturing
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- MULN Consumer Discretionary
- QLGN Health Care
- Exchange
- MULN Nasdaq
- QLGN Nasdaq
- Market Cap
- MULN 4.1M
- QLGN 2.7M
- IPO Year
- MULN N/A
- QLGN N/A
- Fundamental
- Price
- MULN $2.54
- QLGN $3.60
- Analyst Decision
- MULN
- QLGN
- Analyst Count
- MULN 0
- QLGN 0
- Target Price
- MULN N/A
- QLGN N/A
- AVG Volume (30 Days)
- MULN 5.6M
- QLGN 226.0K
- Earning Date
- MULN 08-12-2024
- QLGN 11-29-2024
- Dividend Yield
- MULN N/A
- QLGN N/A
- EPS Growth
- MULN N/A
- QLGN N/A
- EPS
- MULN N/A
- QLGN N/A
- Revenue
- MULN $156,570.00
- QLGN N/A
- Revenue This Year
- MULN N/A
- QLGN N/A
- Revenue Next Year
- MULN N/A
- QLGN N/A
- P/E Ratio
- MULN N/A
- QLGN N/A
- Revenue Growth
- MULN N/A
- QLGN N/A
- 52 Week Low
- MULN $1.60
- QLGN $3.55
- 52 Week High
- MULN $2,100.00
- QLGN $39.15
- Technical
- Relative Strength Index (RSI)
- MULN 37.23
- QLGN 25.42
- Support Level
- MULN $1.60
- QLGN $3.71
- Resistance Level
- MULN $3.68
- QLGN $4.56
- Average True Range (ATR)
- MULN 0.47
- QLGN 0.65
- MACD
- MULN 0.72
- QLGN -0.06
- Stochastic Oscillator
- MULN 45.19
- QLGN 2.08
About MULN Mullen Automotive Inc.
Mullen Automotive Inc is engaged in manufacturing electric vehicles and energy solutions. The company strives to make electric vehicles more accessible by building an end-to-end ecosystem that takes care of all aspects of electric vehicle ownership. The Company owns and partners with several synergistic businesses, all working towards the same goal of creating clean and scalable electric vehicles and energy solutions. The company has two segments Bollinger and Mullen/ELMS, which generates revenue.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.